Upstream Bio

Upstream Bio Raises $153M in Series B

Upstream Bio has successfully raised $153M in a Series B at a $800M valuation led by Fidelity, Viking Global.

Company Overview

Upstream Bio is a Biotech company headquartered in Waltham, MA, founded in 2020 with 120+ employees.

Developing antibody therapeutics for inflammatory diseases

Fundraising Details

• Amount Raised: $153M
• Round Type: Series B
• Valuation: $800M
• Date: 2024-09-10
• Investors: Fidelity, Viking Global

About Upstream Bio

Developing antibody therapeutics for inflammatory diseases The company is positioned in the Biotech sector, serving a growing market with innovative solutions.

Key Information

• Headquarters: Waltham, MA
• Founded: 2020
• Team Size: 120+
• Industry: Biotech

What This Means

This funding round demonstrates strong investor confidence in Upstream Bio's vision and execution. The capital will likely be used to:

• Scale Operations: Expand the team and operational capacity
• Product Development: Enhance existing products and develop new features
• Market Expansion: Enter new markets and strengthen presence in existing ones
• Technology Investment: Invest in infrastructure and technology capabilities

Industry Context

The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Upstream Bio's successful fundraising reflects the strong fundamentals and growth potential in this space.

Valuation Milestone

Reaching a $800M valuation marks an important milestone for Upstream Bio, positioning the company among notable players in the Biotech industry.

Looking Ahead

With this new capital, Upstream Bio is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.

This fundraising news was reported on 2024-09-10. For more information about Upstream Bio, visit their headquarters at Waltham, MA.